After the Human Genome Project was completed in 2003, early successes in genomic medicine fell short of the initial high expectations. But today, a potent mix of influences — including innovation in biology and technology, market demand and consumerism — is furthering an evolution that crosses industries. Healthcare providers can now personalize care plans thanks to lower sequencing costs that allow genomic data to be combined with electronic health data. Life sciences companies can develop targeted therapies that prevent and alleviate disease symptoms. To capitalize on new advances in science, cognitive computing, analytics and drug discovery, senior leaders across the ecosystem should act quickly to: make genomic medicine a key component of enterprise strategy; address relevant skill gaps; and determine how partnering can bolster critical capabilities.

1. The evolving promise of
genomic medicine
IBM Institute for Business Value
2000 2005 2010 2015
2001 2003 2014
Innovation in biology and technology
Growing market demand for targeted
products
Consumerism and regulatory attention
bring new media attention
Announcement
of Human
Genome Project
Human Genome
Project declared
complete
Exploring major changes ahead from
genomic medicine
The growing use of a new genomic health
record
Opportunities for radical industry transformation
across healthcare and life sciences
Greater benefits for stakeholders
Genomic medicine and technology
improvements offer substantial benefits
Translational
medicine
Data analytics will
include cognitive
computing platforms
Achieve insights on
with high efficacy and
low side effects
Share and validate
insights among
communities
Personalized
healthcare
Offer faster “second
opinions” with higher
confidence and rigor
Disease progression
models will guide
physicians
Oncology is expected
to benefit first
Sequencing
Becomes faster,
cheaper and more
accurate
Aggregate and
analyze information
from multiple sources
Analytics capabilities
increase raw data's
value
Register to read this report: http://bit.ly/genomicpaper
© Copyright IBM Corporation 2014. IBM, the IBM logo and ibm.com are trademarks or registered trademarks of IBM Corp., registered in many
jurisdictions worldwide. Other product or service names might be trademarks of IBM or other companies. A current list of IBM trademarks is
available on the Web at “Copyright and trademark information” at ibm.com/legal/copytrade.shtml
GBL03022-USEN-00